JP7458622B2 - Substances that reduce the resistance of antibiotic-resistant microorganisms and methods for reducing the resistance of antibiotic-resistant microorganisms - Google Patents
Substances that reduce the resistance of antibiotic-resistant microorganisms and methods for reducing the resistance of antibiotic-resistant microorganisms Download PDFInfo
- Publication number
- JP7458622B2 JP7458622B2 JP2019169923A JP2019169923A JP7458622B2 JP 7458622 B2 JP7458622 B2 JP 7458622B2 JP 2019169923 A JP2019169923 A JP 2019169923A JP 2019169923 A JP2019169923 A JP 2019169923A JP 7458622 B2 JP7458622 B2 JP 7458622B2
- Authority
- JP
- Japan
- Prior art keywords
- antibiotic
- manganese
- resistance
- bacteria
- resistant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000005700 microbiome Species 0.000 title claims description 33
- 230000003115 biocidal effect Effects 0.000 title claims description 21
- 239000000126 substance Substances 0.000 title claims description 16
- 238000000034 method Methods 0.000 title claims description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 72
- 239000011572 manganese Substances 0.000 claims description 43
- 229960005322 streptomycin Drugs 0.000 claims description 36
- 229910052748 manganese Inorganic materials 0.000 claims description 26
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 25
- 239000003242 anti bacterial agent Substances 0.000 claims description 23
- 229940088710 antibiotic agent Drugs 0.000 claims description 18
- 206010059866 Drug resistance Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 241000207199 Citrus Species 0.000 claims description 8
- 235000020971 citrus fruits Nutrition 0.000 claims description 8
- 241001604418 Aromia bungii Species 0.000 claims description 7
- -1 biculare Species 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000589634 Xanthomonas Species 0.000 claims description 2
- 235000003840 Amygdalus nana Nutrition 0.000 claims 3
- 235000011432 Prunus Nutrition 0.000 claims 3
- 241000220299 Prunus Species 0.000 claims 3
- 235000014774 prunus Nutrition 0.000 claims 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 241000589636 Xanthomonas campestris Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 39
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 241000233866 Fungi Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000005802 Mancozeb Substances 0.000 description 4
- 235000006040 Prunus persica var persica Nutrition 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 244000000005 bacterial plant pathogen Species 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 244000144730 Amygdalus persica Species 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- ANHQLUBMNSSPBV-UHFFFAOYSA-N 4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical group C1=CN=C2NC(=O)COC2=C1 ANHQLUBMNSSPBV-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010027146 Melanoderma Diseases 0.000 description 2
- 229930182764 Polyoxin Natural products 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 241000985670 Xanthomonas arboricola pv. pruni Species 0.000 description 2
- 239000003905 agrochemical Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002697 manganese compounds Chemical class 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- YEBIHIICWDDQOL-YBHNRIQQSA-N polyoxin Polymers O[C@@H]1[C@H](O)[C@@H](C(C=O)N)O[C@H]1N1C(=O)NC(=O)C(C(O)=O)=C1 YEBIHIICWDDQOL-YBHNRIQQSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 241000726119 Acidovorax Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000624151 Pseudomonas amygdali pv. morsprunorum Species 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101100257766 Streptococcus agalactiae serotype III (strain NEM316) strA gene Proteins 0.000 description 1
- 101100043717 Streptomyces griseus aphD gene Proteins 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 229910001361 White metal Inorganic materials 0.000 description 1
- 241001272684 Xanthomonas campestris pv. oryzae Species 0.000 description 1
- 241000589655 Xanthomonas citri Species 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- SDPBZSAJSUJVAT-UHFFFAOYSA-N carbonic acid;manganese Chemical compound [Mn].OC(O)=O SDPBZSAJSUJVAT-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 150000002259 gallium compounds Chemical class 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- YKSNLCVSTHTHJA-UHFFFAOYSA-L maneb Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S YKSNLCVSTHTHJA-UHFFFAOYSA-L 0.000 description 1
- 229920000940 maneb Polymers 0.000 description 1
- 239000011656 manganese carbonate Substances 0.000 description 1
- 235000006748 manganese carbonate Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000003032 phytopathogenic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 101150098466 rpsL gene Proteins 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
- 239000010969 white metal Substances 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
本発明は、抗生物質耐性微生物に対し、その抗生物質耐性を低下させる物質及びその抗生物質耐性を低下させる方法に関する。 The present invention relates to a substance that reduces the antibiotic resistance of antibiotic-resistant microorganisms, and a method for reducing the antibiotic resistance.
従来の抗生物質および他の抗菌薬に対して耐性を有する病原性微生物が出現していることが世界的に大きな問題になっている。例えば、院内感染性の原因である黄色ブドウ球菌(Staphylococcus aureus)は、1940年代の初頭にペニシリンによって十分な殺菌効果が認められていたが、1960年代の後期までに80%超の黄色ブドウ球菌がペニシリンに対して耐性となり、1972年までに2%の黄色ブドウ球菌がメシチリン耐性であることが認められるようになった。なお、メシチリン耐性菌の割合は2002年までに57.1%まで上昇し続けたと報告されている。 The emergence of pathogenic microorganisms that are resistant to conventional antibiotics and other antimicrobial agents is a major problem worldwide. For example, in the early 1940s, penicillin was found to have a sufficient sterilizing effect on Staphylococcus aureus, which causes hospital-acquired infections, but by the late 1960s, more than 80% of Staphylococcus aureus had been killed. It became resistant to penicillin, and by 1972 it was recognized that 2% of Staphylococcus aureus were resistant to methicillin. It is reported that the percentage of methicillin-resistant bacteria continued to rise to 57.1% by 2002.
このような抗生物質耐性微生物に対し、特開2019-135269号公報は、メチシリン耐性黄色ブドウ球菌(MRSA)、バンコマイシン耐性エンテロコッカス・フェカリス(VRE)、大腸菌O157:H7、フルオロキノロン耐性チフス菌等に対し、ガリウム化合物を被験体に投与することにより、細菌及び真菌などの細胞外微生物により引き起こされる感染症を予防又は治療する方法を開示している(特許文献1)。 Regarding such antibiotic-resistant microorganisms, Japanese Patent Application Publication No. 2019-135269 discloses that it is effective against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), Escherichia coli O157:H7, fluoroquinolone-resistant Salmonella typhi, etc. discloses a method for preventing or treating infectious diseases caused by extracellular microorganisms such as bacteria and fungi by administering a gallium compound to a subject (Patent Document 1).
抗生物質耐性微生物に関する問題は、ヒト及び家畜に対する抗生物質耐性微生物のみならず、植物病原細菌の抗生物質耐性微生物についても同様のことがいえる。例えば、野菜の黒腐病や腐敗病、果樹の黒点病や黒斑病、稲のもみ枯細菌病などの殺菌剤の有効成分として抗生物質が使用されている。そのため、抗生物質を作物に継続的に散布することによって農場や農作物に存在している微生物が抗生物質に対する耐性を獲得し、農業従事者に多大な経済的負担をもたらすことが予想される。薬剤耐性細菌によって引き起こされる病害は、抗生物質に耐性の細菌の顕在化により抗生物質による防除が困難となる。さらに、抗生物質耐性細菌に有効な新規抗生物質の開発には時間もコストも多大なものとなるため一企業又は一個人での対応は限界があるとともに、仮に新規抗生物質が開発されたとしても、その新規抗生物質にも耐性を示す細菌が出現する可能性が高い。 The same problem regarding antibiotic-resistant microorganisms applies not only to antibiotic-resistant microorganisms for humans and livestock, but also to antibiotic-resistant microorganisms for plant pathogenic bacteria. For example, antibiotics are used as active ingredients in fungicides to treat black rot and rot of vegetables, black spot and black spot of fruit trees, and bacterial blight of rice. Therefore, it is expected that continuous spraying of antibiotics on crops will cause microorganisms present in farms and crops to acquire resistance to antibiotics, resulting in a significant economic burden on farmers. Diseases caused by drug-resistant bacteria become difficult to control with antibiotics due to the emergence of antibiotic-resistant bacteria. Furthermore, developing new antibiotics that are effective against antibiotic-resistant bacteria requires a great deal of time and cost, so there are limits to what a single company or individual can do, and even if a new antibiotic were developed, There is a high possibility that bacteria that are resistant to these new antibiotics will emerge.
そこで、本発明は、抗生物質に対して耐性を低下させる物質又は生育を低下させる物質を提供することを目的とする。 Therefore, an object of the present invention is to provide a substance that reduces resistance to antibiotics or a substance that reduces growth.
上記課題を解決するため、本発明者らは、細菌の抗生物質耐性に影響を与える物質を種々検討したところ、偶然にも、マンガン(Mn)が細菌の抗生物質に対する耐性を低下させるとの知見を得た。 In order to solve the above problems, the present inventors investigated various substances that affect the antibiotic resistance of bacteria, and coincidentally found that manganese (Mn) reduces the resistance of bacteria to antibiotics. I got it.
本発明はかかる知見に基づきなされたものであり、微生物に対し薬剤耐性を低下させるための物質として使用されるマンガンを提供するものである。 The present invention was made based on this knowledge, and provides manganese that can be used as a substance for reducing drug resistance in microorganisms.
本発明はまた、微生物に対する薬剤耐性を低下させるための薬剤を製造するためのマンガンの使用を提供するものである。 The present invention also provides the use of manganese for manufacturing a drug for reducing drug resistance against microorganisms.
本発明はさらに、抗生物質を含有する薬剤であって、微生物に対し薬剤耐性を低下させる物質としてマンガンを含有することを特徴とする薬剤を提供するものである。 The present invention further provides a drug containing an antibiotic, which is characterized by containing manganese as a substance that reduces drug resistance against microorganisms.
本発明によれば、既存の抗生物質に耐性の微生物が顕在化して治療や防除に効果がない場合、マンガンとともに抗生物質を処理(投与や散布)することで、微生物に対し薬剤耐性を低下させることができる。これを、抗生物質を含有する薬剤に含有させれば、細菌のような微生物に対し薬剤耐性を低下させることができるため、既存の抗生物質でも治療や防除において高い効果が得られる。 According to the present invention, when microorganisms resistant to existing antibiotics become evident and treatment or control is ineffective, drug resistance of the microorganisms can be reduced by treating (administering or spraying) the antibiotic together with manganese. By adding this to a drug containing an antibiotic, drug resistance of microorganisms such as bacteria can be reduced, so that even existing antibiotics can be highly effective in treatment and control.
以下、本発明に係る実施形態について詳細に説明する。 The following describes in detail an embodiment of the present invention.
本実施形態において、マンガンは、微生物に対し薬剤耐性を低下させるための物質として使用される。 In this embodiment, manganese is used as a substance to reduce drug resistance against microorganisms.
マンガンは、原子番号25の元素であり、元素記号は「Mn」である。マンガンは、自然界では硫化物、酸化物、炭酸塩、ケイ酸塩、リン酸塩、ホウ酸塩など、様々な形で、100種類以上の鉱物に含まれて存在する(NAS-NRC 1973)。主要鉱石としてパイロルース鉱、サイロメレーン鉱、菱マンガン鉱、テフロ石などがあることが知られている。地殻に広く分布し、平均存在量950ppm、海水中には2μg/l含まれる。単体は銀白色の金属であるが、炭素を含むと灰色となる。α型、β型、γ型、δ型の4つの同素体が存在するが、本発明においては、いずれの同素体も利用することが可能である。 Manganese is an element with an atomic number of 25, and its element symbol is "Mn". Manganese exists in nature in more than 100 minerals in various forms, including sulfides, oxides, carbonates, silicates, phosphates, and borates (NAS-NRC 1973). It is known that the main ores include pyroluthite, psilomelaneite, rhodochrosite, and tephrite. It is widely distributed in the earth's crust, with an average abundance of 950 ppm and 2 μg/l in seawater. Alone, it is a silvery-white metal, but when it contains carbon, it becomes gray. There are four allotropes: α-type, β-type, γ-type, and δ-type, and any of the allotropes can be used in the present invention.
本実施形態において、「マンガン」はマンガン化合物を含むものとする(以下、これらをまとめて「マンガン等」という。)。主なマンガン化合物としては、例えば、塩化マンガン(II)(Manganese chloride、MnCl2)、硫酸マンガン(II)(Manganese sulfate、MnSO4)、四酸化三マンガン(Manganese oxide、Mn3O4)、二酸化マンガン(Manganese dioxide、MnO2)、過マンガン酸カリウム(Potasium permanganate、KMnO4)、ホウ酸マンガン(8水和物)(Manganese borate、MnB4O7・8H2O)、炭酸マンガン(II)(Manganese carbonate、MnCO3)、メチルシクロペンタジエニルマンガントリカルボニル(Methylcyclopentadienyl manganese tricarbonyl(MMT)、C9H7MnO3)、マンネブ(Maneb、C4H6N2S4Mn)、マンコゼブ(Mancozeb、[C4H6N2S4Mn]x(Zn)y、x:y=10:1)等を挙げることができる。
In this embodiment, "manganese" includes manganese compounds (hereinafter, these are collectively referred to as "manganese etc."). Main manganese compounds include, for example, manganese chloride (MnCl 2 ), manganese sulfate (MnSO 4 ), manganese oxide (Mn 3 O 4 ), and manganese dioxide. Manganese (MnO 2 ), Potassium permanganate (KMnO 4 ), Manganese borate (octahydrate) (MnB 4 O 7・8H 2 O), Manganese (II) carbonate ( Manganese carbonate, MnCO 3 ), Methylcyclopentadienyl manganese tricarbonyl (MMT), C 9 H 7 MnO 3 ), Maneb (C 4 H 6 N 2 S 4 Mn), Mancozeb, Examples include [C 4 H 6 N 2 S 4 Mn]x(Zn)y, x:y=10:1).
本実施形態において、微生物は、細菌、特に、植物病原細菌を挙げることができ、具体的には、アシドボラックス(Acidovorax)属細菌、バークホルデリア(Burkholderia)属細菌、シュードモナス(Pseudomonas)属細菌、ラルストニア(Ralstonia)属細菌及びキサントモナス(Xanthomonas)属細菌からなる群から選択された少なくとも1つを上げることができ、より具体的には、ウメかいよう病菌、モモせん孔細菌病菌、カンキツかいよう病菌からなる群から選択された少なくとも1種を挙げることができる。 In this embodiment, the microorganism can include bacteria, particularly plant pathogenic bacteria, and specifically, bacteria of the genus Acidovorax, bacteria of the genus Burkholderia, bacteria of the genus Pseudomonas. , at least one selected from the group consisting of bacteria of the genus Ralstonia and bacteria of the genus Xanthomonas, and more specifically, the bacteria consisting of canker bacterium, peach borer bacterium, and citrus canker bacterium. At least one selected from the group can be mentioned.
本実施形態において、薬剤としては、抗生物質を挙げることができる。抗生物質とは、狭義には、微生物が産生し他の微生物の発育を阻害する物質をいい、広義には、微生物が産生したものを化学修飾したり人工的に合成された抗菌剤、腫瘍細胞のような他の微生物以外の細胞の増殖や機能を阻害する物質を含む。抗生物質としては、例えば、ストレプトマイシン、ペニシリン、アクチノマイシン、リファンピシン、ホスホマイシン、バンコマイシン、クロラムフェニコール等を挙げることができる。 In this embodiment, the drug may include antibiotics. Antibiotics, in a narrow sense, refer to substances produced by microorganisms that inhibit the growth of other microorganisms, and in a broader sense, they refer to substances produced by microorganisms that are chemically modified or artificially synthesized, antibacterial agents, and tumor cells. Contains substances that inhibit the growth and function of other non-microbial cells, such as Examples of antibiotics include streptomycin, penicillin, actinomycin, rifampicin, fosfomycin, vancomycin, chloramphenicol, and the like.
本実施形態において、「薬剤耐性を低下させる」とは、広義には、薬剤耐性を有する微生物の最小生育阻止濃度(MIC)を薬剤の防除効果が得られる程度にまで低下させることを意味し、狭義には、ストレプトマイシン耐性の微生物に対するストレプトマイシンの最小生育阻止濃度(MIC)が18,000ppmだったものを500ppmに低下させ、ストレプトマイシンによる防除効果が得られるようになることを意味する。 In the present embodiment, "reducing drug resistance" in a broad sense means lowering the minimum inhibitory concentration (MIC) of microorganisms with drug resistance to an extent that the control effect of the drug can be obtained, In a narrow sense, this means that the minimum inhibitory concentration (MIC) of streptomycin against streptomycin-resistant microorganisms has been lowered from 18,000 ppm to 500 ppm, allowing streptomycin to have a control effect.
マンガン等が微生物の薬剤耐性を低下させるメカニズムは不明であるが、ある薬剤に感受性の微生物が増殖していく過程でマンガン等が染色体上の遺伝子の突然変異を防止する、突然変異した微生物の外来性の耐性遺伝子を取り込むことをマンガン等が防止する、薬剤耐性を獲得した耐性プラスミドの接合伝達をマンガン等が防止する、等の理由が推察される。なお、マンガン単独では微生物の生育を阻害する効果は認められない。 The mechanism by which manganese and other substances reduce the drug resistance of microorganisms is unknown, but manganese and other substances prevent the mutation of genes on chromosomes during the proliferation of microorganisms that are sensitive to certain drugs. The reasons for this are thought to be that manganese and the like prevent the incorporation of sexual resistance genes, and that manganese and the like prevent the conjugative transfer of resistance plasmids that have acquired drug resistance. Note that manganese alone has no effect of inhibiting the growth of microorganisms.
本実施形態において、マンガン等は、微生物に対する薬剤耐性を低下させるための薬剤を製造するために使用される。 In this embodiment, manganese and the like are used to produce a drug for reducing drug resistance against microorganisms.
抗生物質を含有する薬剤としては特に限定はなく、従来から抗生物質を含有することができる農薬、医薬、動物薬等を挙げることができる。 There are no particular limitations on drugs containing antibiotics, and examples thereof include agricultural chemicals, pharmaceuticals, veterinary drugs, etc. that can conventionally contain antibiotics.
農薬製造におけるマンガン等の添加量(濃度)は、300~3000ppmであることが好ましい。薬剤耐性の獲得を予防又は低下させる効果はマンガン等の濃度依存的に向上するため、300ppm未満では効果が得られにくい。一方、3000ppm以上添加しても作物に悪影響はないが、効果が頭打ちになるため、上限を3000ppmとした。 The amount (concentration) of manganese etc. added in the production of agricultural chemicals is preferably 300 to 3000 ppm. The effect of preventing or reducing the acquisition of drug resistance increases depending on the concentration of manganese, etc., so it is difficult to obtain an effect at less than 300 ppm. On the other hand, although adding more than 3000ppm will not have any negative effects on crops, the effect will reach a plateau, so the upper limit was set at 3000ppm.
本実施形態において、本発明の薬剤耐性を低下させる効果に影響を与えない範囲で、かつ、薬学上許容できる範囲で、他の成分を配合することもできる。配合可能な成分としては、例えば、液体担体、固体担体、界面活性剤(乳化剤、分散剤、消泡剤等)、補助剤等が挙げられる。より具体的には、液体担体としては、リン酸緩衝液、炭酸緩衝液が挙げられる。固体担体としては、カオリン、粘土、石英、モンモリロナイト、珪藻土等の天然鉱物粉末、結晶性セルロース、コーンスターチ、ゼラチン、アルギン酸等の高分子性天然物が挙げられ、これらの一種又は二種以上を混合して使用することができる。界面活性剤としては、ポリオキシンエチレン-脂肪酸エステル、ポリオキシンエチレン-脂肪アルコールエーテル等が上げられる。補助剤としては、カルボキシメチルセルロース、澱粉等が挙げられる。 In this embodiment, other components can also be blended within a range that does not affect the effect of reducing drug resistance of the present invention and within a pharmaceutically acceptable range. Examples of components that can be blended include liquid carriers, solid carriers, surfactants (emulsifiers, dispersants, antifoaming agents, etc.), adjuvants, and the like. More specifically, liquid carriers include phosphate buffers and carbonate buffers. Examples of solid carriers include natural mineral powders such as kaolin, clay, quartz, montmorillonite, and diatomaceous earth, and polymeric natural products such as crystalline cellulose, cornstarch, gelatin, and alginic acid. can be used. Examples of the surfactant include polyoxin ethylene-fatty acid ester, polyoxin ethylene-fatty alcohol ether, and the like. Examples of auxiliary agents include carboxymethyl cellulose and starch.
薬剤の剤型としては種々の剤型を選択することができ、例えば、粉剤、粒剤、粉粒剤、粉末、水和剤、水溶剤、乳剤、液剤、油剤、エアゾル、ペースト剤、くん煙剤、くん蒸剤、塗布剤、マイクロカプセル剤、パック剤、フロアブル剤等を挙げることができる。 Various dosage forms can be selected as the dosage form of the drug, such as powder, granule, powder, powder, wettable powder, aqueous solution, emulsion, liquid, oil, aerosol, paste, and smoke. agent, fumigation agent, coating agent, microcapsule agent, pack agent, flowable agent, etc.
1.SM耐性を低下または生育を抑制する物質の検討
(1)実験方法
供試細菌として、ストレプトマイシン(SM)に対して耐性を有する、モモせん孔細菌病菌(Xanthomonas arboricola pv. pruni)、カンキツかいよう病菌(Xanthomonas citri subsp. citri)、ウメかいよう病菌(Pseudomonas syringae pv. morsprunorum)を用い、これら植物病原細菌のSM耐性を低下または生育を抑制する物質を検討した。
1. Examination of substances that reduce SM resistance or inhibit growth (1) Experimental method The test bacteria used were the peach bore bacteria (Xanthomonas arboricola pv. pruni), the citrus canker bacteria (Xanthomonas citri subsp. citri), and the plum canker bacteria (Pseudomonas syringae pv. morsprunorum), all of which are resistant to streptomycin (SM), and substances that reduce the SM resistance or inhibit the growth of these plant pathogenic bacteria were examined.
リンゴ果汁40.0 ml、Ca(NO3)2・4H2O 0.5 g、Na2HPO4・12H2O2.0g、Peptone 5.0 g、Agar15.0 g、蒸留水960.0mlからなるASA培地(森山ら,2016)にSMとともにMn0.3、1.5および3.0 g/Lで混和した培地で、SM感性菌および耐性菌(MIC:500および>16000 ppm)を25℃で3日間培養して生育を調査した。 ASA medium ( Moriyama et al . , (2016), SM-sensitive and resistant bacteria (MIC: 500 and >16000 ppm) were cultured at 25°C for 3 days in a medium mixed with SM at 0.3, 1.5, and 3.0 g/L of Mn to investigate their growth.
(2)結果
表1に、マンガン添加ASA培地での植物病原細菌に対するストレプトマイシンの最小生育阻止濃度(ppm)の測定結果を示す。表1中、「ストレプトマイシン耐性」とはMIC:500及び>16000 ppmでSMが効かず感受性が低い細菌を意味し、「ストレプトマイシン感性」とはMICが15.6ppm以下など低く、一般的にSMが効き感受性が高い細菌を意味する。また、それぞれ、菌株番号が異なる複数の細菌について実施した。
(2) Results Table 1 shows the measurement results of the minimum growth inhibitory concentration (ppm) of streptomycin against plant pathogenic bacteria on the ASA medium supplemented with manganese. In Table 1, "streptomycin resistant" refers to bacteria with a low MIC of MIC: 500 and >16000 ppm, to which SM is not effective, and "streptomycin sensitive" refers to bacteria with a low MIC of 15.6 ppm or less, and in which SM is generally not effective. Denotes highly susceptible bacteria. In addition, experiments were conducted on multiple bacteria with different strain numbers.
SMとともにMnを3.0 g/L混和したASA培地でのSM耐性菌のMICは、モモせん孔細菌病菌では125~500 ppm、さらにウメかいよう病菌およびカンキツかいよう病菌でも>2000 ppmから2000 ppmに低下した。Mnのみの混和では供試菌の生育に影響はなかった。 The MIC of SM-resistant bacteria on ASA medium containing SM and Mn at 3.0 g/L was 125 to 500 ppm for peach borer fungi, and further decreased from >2000 ppm to 2000 ppm for plum and citrus fungi. Mixing only Mn had no effect on the growth of the test bacteria.
以上の結果から、MnはSM耐性に関わるstrA遺伝子(Scholz et al.,1989)などの発現に影響する可能性があると推察された。 These results suggest that Mn may affect the expression of genes such as strA (Scholz et al., 1989), which are involved in SM resistance.
なお、Mnに替えて、Zn、ZnO、マンゼブ剤((C4H6MnN2S4)xZny)を用いて同様の試験を実施したところ、ZnおよびZnOは3.0 g/L、マンゼブは散布濃度(1333 ppm)において各単体でSM感受性に関係なく全供試菌の生育を抑制した。マンゼブ剤はモモの糸状菌病だけでなくせん孔細菌病、さらにウメやカンキツのかいよう病防除に有効である可能性がある。 In addition, when a similar test was conducted using Zn, ZnO, and mancozeb agent ((C4H6MnN2S4)xZny) instead of Mn, it was found that Zn and ZnO were 3.0 g/L, and mancozeb was each alone at the spray concentration (1333 ppm). The growth of all tested bacteria was inhibited regardless of SM susceptibility. Mancozeb may be effective in controlling not only filamentous fungal diseases of peaches, but also boring bacterial diseases, as well as canker diseases of plums and citrus.
2.マンガンの添加量がストレプトマイシン耐性植物病原細菌の耐性に与える影響
(1)実験方法
供試細菌として、ストレプトマイシン(SM)に対して耐性を有する、モモせん孔細菌病菌(Xanthomonas arboricola pv. pruni)を用い、マンガンの添加量がストレプトマイシンの最小生育阻止濃度(ppm)に与える影響を検討した。
2. Effect of the amount of manganese added on the resistance of streptomycin-resistant phytopathogenic bacteria (1) Experimental method As the test bacterium, peach borer fungus (Xanthomonas arboricola pv. pruni), which is resistant to streptomycin (SM), was used. The effect of the amount of manganese added on the minimum growth inhibitory concentration (ppm) of streptomycin was investigated.
Mnを0.3、1.5および3.0 g/L でそれぞれ添加したASA培地をオートクレーブ滅菌し、その後50℃にしたこれらの培地に、ストレプトマイシンを1.95、3.90、7.80、15.6、31.3、62.5、125、250、500、1000、2000、4000、8000および16000ppmとなるようにそれぞれ加えて平板培地を作成した。この平板培地に24~48時間培養した供試細菌を約108cfu/mlとなるように滅菌蒸留水に懸濁して細菌懸濁を作成した。この細菌懸濁液を前述の平板培地に滅菌した綿棒で塗布して、25℃で3日間培養して細菌の生育の有無を調査した。 ASA medium supplemented with 0.3, 1.5, and 3.0 g/L Mn was sterilized by autoclaving, and then heated to 50°C. Streptomycin was added to these media at concentrations of 1.95, 3.90, 7.80, 15.6, 31.3, 62.5, 125, 250, 500, 1000, 2000, 4000, 8000, and 16000 ppm to prepare plate media. Test bacteria were cultured on these plate media for 24 to 48 hours, and suspended in sterile distilled water to a concentration of approximately 10 8 cfu/ml to prepare a bacterial suspension. This bacterial suspension was applied to the aforementioned plate media with a sterile cotton swab, and the media was cultured at 25°C for 3 days to examine whether the bacteria grew or not.
(2)結果
結果を図1及び図2に示す。図1はMn3.0g/lを添加したASA培地におけるSM各濃度で培養した結果を示し、図2はMn無添加のASA培地におけるSM各濃度で培養した結果を示す。ストレプトマイシン無添加でMnを0.3、1.5および3.0 g/L でそれぞれ添加したASA培地(図1左上)では、供試細菌はストレプトマイシンおよびMnが無添加のASA培地(図2左上)と同等の生育であった。Mnは供試細菌の生育に影響しなかった。一方、Mnとともにストレプトマイシンを添加した培地(図1)では、供試細菌に対するストレプトマイシンのMICは低下した。
(2) Results The results are shown in Figures 1 and 2. Figure 1 shows the results of culturing at various concentrations of SM in ASA medium supplemented with 3.0 g/l of Mn, and Figure 2 shows the results of culturing at various concentrations of SM in ASA medium without Mn addition. In ASA medium without streptomycin and with Mn added at 0.3, 1.5, and 3.0 g/L (Fig. 1, upper left), the test bacteria grew at the same level as in ASA medium without streptomycin and Mn (Fig. 2, upper left). there were. Mn did not affect the growth of the test bacteria. On the other hand, in the medium containing streptomycin together with Mn (Fig. 1), the MIC of streptomycin against the test bacteria decreased.
モモせん孔細菌病菌、カンキツかいよう病菌を用いて同様の実験を実施した。その結果、Mnを3.0 g/L添加した培地において、モモせん孔細菌病菌ではストレプトマイシン耐性菌(MIC:500および>16000 ppm)のMICが125~500 ppm、さらにウメかいよう病菌およびカンキツかいよう病菌でもMICが>2000 ppmから2000 ppmに低下した。 Similar experiments were conducted using peach borer fungi and citrus canker fungi. As a result, in a medium supplemented with 3.0 g/L of Mn, the MIC of streptomycin-resistant bacteria (MIC: 500 and >16000 ppm) was 125 to 500 ppm for peach borer fungi, and the MIC for plum canker and citrus fungi was 125 to 500 ppm. It decreased from >2000 ppm to 2000 ppm.
Claims (3)
前記微生物が、ウメかいよう病菌、モモせん孔細菌病菌、カンキツかいよう病菌からなる群から選択された少なくとも1種であり、
前記抗生物質がストレプトマイシンである、
前記マンガンの使用。 The use of manganese for the production of a drug for reducing the drug resistance of drugs containing antibiotics against microorganisms,
The microorganism is at least one selected from the group consisting of a plum canker, a peach borer, and a citrus canker,
the antibiotic is streptomycin;
Use of said manganese.
前記微生物が、ウメかいよう病菌、モモせん孔細菌病菌、カンキツかいよう病菌からなる群から選択された少なくとも1種であり、
前記抗生物質がストレプトマイシンである、
前記薬剤。 A drug characterized by containing manganese as a substance that reduces the drug resistance of drugs containing antibiotics against microorganisms,
The microorganism is at least one selected from the group consisting of a plum canker, a peach borer, and a citrus canker,
the antibiotic is streptomycin;
Said drug.
前記微生物が、ウメかいよう病菌、モモせん孔細菌病菌、カンキツかいよう病菌からなる群から選択された少なくとも1種であり、
前記抗生物質がストレプトマイシンである、
前記方法。 A method for reducing drug resistance of an antibiotic-resistant microorganism, comprising adding manganese to a drug containing an antibiotic, thereby reducing drug resistance of the microorganism,
The microorganism is at least one selected from the group consisting of Xanthomonas prunus, Bacillus orbiculare prunus, and Xanthomonas campestris prunus,
The antibiotic is streptomycin.
The method .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019169923A JP7458622B2 (en) | 2019-09-18 | 2019-09-18 | Substances that reduce the resistance of antibiotic-resistant microorganisms and methods for reducing the resistance of antibiotic-resistant microorganisms |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019169923A JP7458622B2 (en) | 2019-09-18 | 2019-09-18 | Substances that reduce the resistance of antibiotic-resistant microorganisms and methods for reducing the resistance of antibiotic-resistant microorganisms |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021046371A JP2021046371A (en) | 2021-03-25 |
JP7458622B2 true JP7458622B2 (en) | 2024-04-01 |
Family
ID=74877713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019169923A Active JP7458622B2 (en) | 2019-09-18 | 2019-09-18 | Substances that reduce the resistance of antibiotic-resistant microorganisms and methods for reducing the resistance of antibiotic-resistant microorganisms |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7458622B2 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000001605A (en) | 1998-06-16 | 2000-01-07 | Kuraray Co Ltd | Polyester resin composition |
JP2003518072A (en) | 1999-12-20 | 2003-06-03 | サ マジェステ ラ レイン デュ シェフ デュ カナダ アグリカルチャー エト アグロアリメンテラー カナダ | Methods and compositions for the treatment and / or prevention of antibiotic-resistant microbial infections |
JP2003171274A (en) | 2001-12-07 | 2003-06-17 | Tomihiko Higuchi | Medicinal composition and disinfectant for treating infection with drug-resistant microorganism |
JP2006513162A (en) | 2002-11-01 | 2006-04-20 | パラテック ファーマシューティカルズ インコーポレイテッド | Transcription factor modulating compounds and methods of use thereof |
JP2010251092A (en) | 2009-04-15 | 2010-11-04 | Panasonic Corp | Electrode structure, low-pressure discharge lamp, illumination device, and image display device |
JP2012162423A (en) | 2011-02-08 | 2012-08-30 | Kyoto Univ | Ruthenium porous body and method for producing the same |
WO2014119519A1 (en) | 2013-01-29 | 2014-08-07 | 日産化学工業株式会社 | Emulsifying pesticide composition having high emulsion stability |
JP2018008971A (en) | 2010-08-12 | 2018-01-18 | マイクロビオン コーポレーション | Bismuth-thiol as disinfectant for used in agricultural, industrial and other use |
JP2019135269A (en) | 2007-04-02 | 2019-08-15 | アイカーン スクール オブ メディスン アット マウント シナイ | Methods for preventing or treating infectious diseases caused by extracellular microorganisms comprising antibacterial-resistant strains using gallium compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2517270B2 (en) * | 1987-04-03 | 1996-07-24 | 住友化学工業株式会社 | Agricultural and horticultural sterilizing composition |
-
2019
- 2019-09-18 JP JP2019169923A patent/JP7458622B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000001605A (en) | 1998-06-16 | 2000-01-07 | Kuraray Co Ltd | Polyester resin composition |
JP2003518072A (en) | 1999-12-20 | 2003-06-03 | サ マジェステ ラ レイン デュ シェフ デュ カナダ アグリカルチャー エト アグロアリメンテラー カナダ | Methods and compositions for the treatment and / or prevention of antibiotic-resistant microbial infections |
JP2003171274A (en) | 2001-12-07 | 2003-06-17 | Tomihiko Higuchi | Medicinal composition and disinfectant for treating infection with drug-resistant microorganism |
JP2006513162A (en) | 2002-11-01 | 2006-04-20 | パラテック ファーマシューティカルズ インコーポレイテッド | Transcription factor modulating compounds and methods of use thereof |
JP2019135269A (en) | 2007-04-02 | 2019-08-15 | アイカーン スクール オブ メディスン アット マウント シナイ | Methods for preventing or treating infectious diseases caused by extracellular microorganisms comprising antibacterial-resistant strains using gallium compounds |
JP2010251092A (en) | 2009-04-15 | 2010-11-04 | Panasonic Corp | Electrode structure, low-pressure discharge lamp, illumination device, and image display device |
JP2018008971A (en) | 2010-08-12 | 2018-01-18 | マイクロビオン コーポレーション | Bismuth-thiol as disinfectant for used in agricultural, industrial and other use |
JP2012162423A (en) | 2011-02-08 | 2012-08-30 | Kyoto Univ | Ruthenium porous body and method for producing the same |
WO2014119519A1 (en) | 2013-01-29 | 2014-08-07 | 日産化学工業株式会社 | Emulsifying pesticide composition having high emulsion stability |
Also Published As
Publication number | Publication date |
---|---|
JP2021046371A (en) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200375193A1 (en) | Pathogen inhibitor | |
EP1845784B1 (en) | Method of treating food products | |
US6099855A (en) | Therapeutic, production and immunostimulatory uses of biocidal compositions | |
US6004587A (en) | Therapeutic, production and immunostimulatory uses of biocidal compositions | |
JP2022529137A (en) | Various Uses of Functionalized Titanium Dioxide Nanoparticle Compounds | |
JP7458622B2 (en) | Substances that reduce the resistance of antibiotic-resistant microorganisms and methods for reducing the resistance of antibiotic-resistant microorganisms | |
CN107041384A (en) | A kind of bactericidal composition and its application containing bacillus amyloliquefaciens and Fluoxastrobin | |
WO2014164694A1 (en) | Application of biofilm formation inhibiting compounds enhances control of citrus canker | |
CN101926830B (en) | Antibacterial agent | |
CN114009443A (en) | Application of pleuromutilin compound in resisting plant pathogenic bacteria | |
CN106818744B (en) | For abolishing the disinfectant of bacterial biofilm | |
Piskaeva et al. | Comparative analysis of the activity of silver nanoparticles against native microflora from poultry processing plants wastes | |
CN113545349B (en) | Application of 1, 3-dicarbonyl-4-trifluoromethyl compound in resisting plant pathogenic bacteria | |
US20040131581A1 (en) | Novel synergistic antimicrobial compositions and methods | |
CN114940977A (en) | Salmonella anatipestifer bacteriophage, bacteriophage composition thereof and application of salmonella anatipestifer bacteriophage in prevention and treatment of salmonella anatipestifer infection diseases | |
CN114272246A (en) | Application of uracil in preparing anti-infective medicine | |
CN109526981B (en) | Nanocomposite g-C3N4Ni, preparation method and application thereof | |
CN112931528A (en) | Safe disinfectant special for raw fish overwintering culture water body and application thereof | |
US3887353A (en) | Diethyl betaaminoethylphosphonate as an algaecide | |
US20230052893A1 (en) | A synergistic bactericide and bacteriostatic organic sanitizing/disinfectant/cleaning formulation | |
KR102731046B1 (en) | Manufacturing method of chitosan oligosaccharide composition having antibacterial lasting effect and the composition manufactured thereby | |
Rajeswari et al. | Antibacterial activity of honey against Staphylococcus aureus from infected wounds | |
Hassanien et al. | The impact of silver and chitosan nanoparticles on A. fumigatus isolates from Ras cheese and sputum of respiratory patients | |
US9949925B2 (en) | Bactericidal compositions and methods for treating pathogenic biofilms | |
CN116941618A (en) | Bactericide composition for preventing and treating anthracnose of avocado |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221007 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230529 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230719 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240307 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240312 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7458622 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |